619-10-3

Usage

Uses

2-Chloro-5-nitrophenol (cas# 619-10-3) is a compound useful in organic synthesis.

InChI:InChI=1/C6H4ClNO3/c7-5-2-1-4(8(10)11)3-6(5)9/h1-3,9H

Upstream product

• 1009-36-5 2-chloro-5-nitroanisole 
• 102236-22-6 1-chloro-2-ethoxy-4-nitrobenzene 
• 121-88-0 5-Nitro-2-aminophenol 
• 5467-64-1 2-acetamidophenyl acetate 
• 108761-49-5 acetic acid-(4-ethoxy-3-chloro-anilide) 
• 171111-66-3 4-ethoxy-5-chloro-2-nitro-aniline 
• 51-19-4 2-aminophenol hydrochloride 
• 4920-79-0 2-chloro-4-nitroanisole 
• 6283-25-6 H₂NC₆H₃(Cl)NO₂ 
• 7758-89-6 copper(I) chloride 
• 5329-14-6 aminosulfonic acid 
• 7440-44-0 pyrographite 
• 1351353-49-5 1-chloro-2-((4-methoxybenzyl)oxy)-4-nitrobenzene 
• 554-84-7 meta-nitrophenol 

Downstream Products

• 6358-06-1 5-amino-2-chlorophenol 
• 64046-47-5 2-chloro-5-nitrophenyl acetate 
• 31191-47-6 2-(4-Bromo-butoxy)-1-chloro-4-nitro-benzene 
• 31185-46-3 4-[5-(2-Chloro-5-nitro-phenoxy)-pentyloxy]-benzenesulfonyl fluoride 
• 31191-48-7 2-(5-Bromo-pentyloxy)-1-chloro-4-nitro-benzene 
• 33814-76-5 2-(2-Chlor-5-nitrophenoxy)-propionitril 
• 3062-53-1 2-(2-bromoethoxy)-1-chloro-4-nitrobenzene 
• 31191-46-5 2-(3-bromopropoxy)-1-chloro-4-nitrobenzene 
• 52427-06-2 2-chloro-5-nitrophenoxyacetic acid 
• 191984-82-4 1-chloro-2-(3-methyl-2-butenyloxy)-4-nitrobenzene 
• 953804-18-7 tert-butyl [2-(2-chloro-5-nitrophenoxy)ethoxy]dimethylsilane 
• 769961-20-8 1-chloro-2-(2-chloro-ethoxy)-4-nitrobenzene 
• 1034475-23-4 1-chloro-2-(2-chloro-ethoxy)-4-isothiocyanato-benzene 
• 1034491-91-2 4-(2-chloro-5-nitro-phenoxymethyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Effect of chloride ion concentration on rapid kinetics of chlorination of regioisomers of nitrophenol by molecular chlorine in aqueous medium using rotating platinum electrode

The rapid kinetics of chlorination of regioisomers of the nitrophenol by molecular chlorine in the presence of chloride ion in aqueous solution has been studied using rotating platinum electrode (RPE). The chloride ion has a catalytic effect on the chlorination reaction. The mechanism suggested explaining the catalytic effect of chloride ion postulates a longer mean life for Cl-Cl dipole induced by the aromatic substrate by electron rearrangement with the chloride ion, which facilitate the electrophilic attack of Cl-Cl on the aromatic substrate in rate determining step. Hence the specific reaction rate varies linearly with the concentration of chloride ion.

Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs

A novel series of 3-benzyloxy-linked pyrimidinylphenylamine derivatives (8a-8s) was designed, synthesized and evaluated for their in vitro anti-HIV activity in MT-4 cell cultures. Most of the compounds inhibited wild-type (wt) HIV-1 replication in the lower micromolar concentration range (EC50 = 0.05-35 μM) with high selectivity index (SI) values (ranged from 10 to >4870). In particular, 8h and 8g displayed excellent antiretroviral activity against wt HIV-1 with low cytotoxicity (EC50 = 0.07 μM, CC 50 >347 μM, SI >4870; EC50 = 0.05 μM, CC 50 = 42 μM, SI = 777, respectively), comparable to that of the marked drug nevirapine (EC50 = 0.113 μM, CC50 >15 μM, SI >133). In order to confirm the binding target, 8h was selected to perform the anti-HIV-1 RT assay. Additionally, preliminary structure activity relationship (SAR) analysis and molecular docking studies of newly synthesized compounds were also discussed, as well as the predicted physicochemical properties.

ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention is for the anti-inflammatory compounds that have an inhibitory activity against protein tyrosine kinases and their pharmaceutical composition(s) containing the compound as the active ingredient. Since the compounds of the present invention can inhibit multiple protein kinases associated with inflammatory diseases and immune disorders, they are useful for their prevention or treatment.

A convenient approach for the deprotection and scavenging of the PMB group using POCl3

A convenient and high yielding approach for the deprotection and scavenging of the p-methoxybenzyl (PMB) group in PMB ethers and PMB esters was developed using POCl3 as the reagent. 4-Methoxybenzyl chloride, a starting material used for the preparation of PMB ethers and esters was regenerated in the deprotection step. This mild and selective procedure tolerates several acid sensitive functional groups. The Royal Society of Chemistry 2013.

COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION

Compounds of the formula (I) are provided, including pharmaceutically acceptable salts thereof: which modulate β-amyloid peptide (β-AP) production, and are useful in the treatment of Alzheimer's Disease and other conditions affected by -amyloid peptide (β-AP) production.

2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS

The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.

PYRROLE ANTIFUNGAL AGENTS

The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.

COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER

The present invention relates to compounds according to the formula I: Where Ra is H or an optionally OH-substituted C1-C3 alkyl; R1 is OR1, an optionally substituted C4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R1 is an optionally substituted C1-C14 hydrocarbyl group or an optionally substituted heterocyclic group;; R2 , R3 and R4 are each independently H, an optionally substituted C1-C4 alkyl group (preferably CH3, CH2CH3 or CF3), halogen (preferably F, Cl, Br), OR, CN, NO2, a C1-C6 thioether, a C1-C6 thioester group, an optionally substituted CO2R group, an optionally substituted COR group or an optionally substituted OCOR group (preferably R4 is H); R is H or an optionally substituted C1-C6 alkyl group; RHET is an optionally substituted heterocyclic group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.

Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors

Inhibition of the VEGF signaling pathway has become a valuable approach in the treatment of cancers. Guided by X-ray crystallography and molecular modeling, a series of 2-aminobenzimidazoles and 2-aminobenzoxazoles were identified as potent inhibitors of VEGFR-2 (KDR) in both enzymatic and HUVEC cellular proliferation assays. In this report we describe the synthesis and structure-activity relationship of a series of 2-aminobenzimidazoles and benzoxazoles, culminating in the identification of benzoxazole 22 as a potent and selective VEGFR-2 inhibitor displaying a good pharmacokinetic profile. Compound 22 demonstrated efficacy in both the murine matrigel model for vascular permeability (79% inhibition observed at 100 mg/kg) and the rat corneal angiogenesis model (ED50 = 16.3 mg/kg).

SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE

The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.